Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Surv...(neral Medicinewhich includes Cardiology ...),Health

Date:5/28/2008

neral Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(a) These results are with one patient and not everyone may experience the

same results.

(b) BETAPLUS is the new name for the MS Pathways(SM) program.

(c) Betaseron is the only immunomodulatory MS therapy that can be stored

at room temperature for greater than 30 days. After reconstitution,

if not immediately used, the product should be refrigerated and used

within 3 hours.

(d) Some restrictions apply. Patients enrolled in any type of government

insurance are not eligible. Void where prohibited by law.

* Trademarks are the property of their respective owners:

-- Betaseron(R) is a registered trademark of Bayer HealthCare

Pharmaceuticals.

-- Copaxone(R) is a registered trademark of Teva Neurosciences, Inc.

-- Rebif(R) is a registered trademark of EMD Serono, Inc.

-- MS Pathways(SM) is a service mark of Bayer HealthCare

Pharmaceuticals.

(1) "Barriers to Treatment C
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon
2. Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD
3. Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD
4. Study: Doctors Significantly Less Likely to Provide Women with Treatments to Prevent Heart Attacks
5. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Paramed Systems Achieves Significant Business Milestone in the Offshore Oil and Gas Evacuation Market
8. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
9. U.S. Patent Office Allows Another Significant VNUS Patent
10. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
11. Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence